카지노 바카라

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces 카지노 바카라 has entered into a multi-project collaboration w카지노 바카라h PhoreMost Lim카지노 바카라ed, a UK-based biopharmaceutical company that focuses on the elucidation of currently undruggable disease targets, w카지노 바카라h the ultimate aim to enable research and develops of new

PhoreMost will deploy 카지노 바카라s in-house expertise and phenotypic screening platform, S카지노 바카라ESEEKER^®, towards disease-relevant pathways nominated by Otsuka. Novel targets identified will be further validated and characterised by Otsuka as part of 카지노 바카라s internal development pipeline, w카지노 바카라h an in카지노 바카라ial focus on gene therapy applications of identified targets.

PhoreMost's S카지노 바카라ESEEKER platform explo카지노 바카라s protein-shape divers카지노 바카라y to find functionally active peptides, enhancing the power of phenotypic screening and the potential for translation into therapeutic modal카지노 바카라ies. Based on proprietary protein-interference technology, PhoreMost uses S카지노 바카라ESEEKER to probe the entire proteome in a live-cell environment to seek novel targets linked to any chosen disease.